Drug intelligence / Profile preview

CAM-1108

Development stage: Preclinical
Lead developer: Cambrian Bio

Overview

CAM-1108 is a preclinical drug candidate being developed by Cambrian Bio (potentially through a subsidiary referred to as Cambrina Biopharma) for the treatment of rare cardiovascular diseases. As a program within Cambrian Bio's distributed pipeline, it is currently in the candidate stage of preclinical development. Specific details regarding its molecular target, mechanism of action, and modality are currently undisclosed as the program is operating in stealth. The drug is part of a broader effort by Cambrian Bio to address the biological drivers of aging and age-related chronic conditions, specifically focusing on rare manifestations within the cardiovascular system.

Beyond the preview

Go deeper on CAM-1108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAM-1108.

Explore the full profile